Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of TAK-755 (rADAMTS13) with minimal to no plasma exchange in immune-mediated thrombotic thrombocytopenic purpura
2022-001940-36Phase 2Active
- Sponsor
- Takeda
- Start
- Dec 2022
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in thrombotic thrombocytopenic purpura (TTP) comparing TAK-755 with minimal to no plasma exchange with Comparator/standard-of-care arm (2 arms). Primary endpoint: Incidence of AEs, SAEs, and AESIs after receiving any dose of investigational product. Started Dec 2022; status: active.
02
Drugs
Apadamtase alfa
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on 2022-001940-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001940-36.